08.02.10
Amgen 2Q
2Q Revenues: $3.8 billion (+3%)
2Q Earnings: $1.2 billion (-5%)
YTD Revenues: $7.4 billion (+6%)
YTD Earnings: $2.4 billion (+4%)
Comments: Total product sales for the quarter were $3.6 billion (-1%). Sales in the U.S. totaled $2.8 billion (-2%) and International sales were up 3% to $826 million. U.S. product sales in the quarter include a $45 million unfavorable impact for certain U.S. Health Care Reform Legislation provisions. Worldwide sales of Aranesp were down 13% to $603 million due to decline in demand. Sales of Epogen were $657 million (+3%). Combined worldwide sales of Neulasta and Neupogen were up 1% to $1.2 billion in the quarter. Sales of Enbrel were $877 million (-2%). Worldwide sales of Sensipar were $172 million (+3%).
2Q Revenues: $3.8 billion (+3%)
2Q Earnings: $1.2 billion (-5%)
YTD Revenues: $7.4 billion (+6%)
YTD Earnings: $2.4 billion (+4%)
Comments: Total product sales for the quarter were $3.6 billion (-1%). Sales in the U.S. totaled $2.8 billion (-2%) and International sales were up 3% to $826 million. U.S. product sales in the quarter include a $45 million unfavorable impact for certain U.S. Health Care Reform Legislation provisions. Worldwide sales of Aranesp were down 13% to $603 million due to decline in demand. Sales of Epogen were $657 million (+3%). Combined worldwide sales of Neulasta and Neupogen were up 1% to $1.2 billion in the quarter. Sales of Enbrel were $877 million (-2%). Worldwide sales of Sensipar were $172 million (+3%).